MARLBOROUGH - Hologic, Inc. (NASDAQ:HOLX) reported fiscal first quarter earnings that fell short of analyst expectations, with revenue of $1.05 billion missing the consensus estimate of $1.07 billion. The medical technology company posted adjusted earnings per share of $1.04, below the analyst forecast of $1.09.

Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this medical device maker have returned +0.

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) yesterday presented new research demonstrating the performance of its Genius AI ® Detection 2.0 software across diverse patient populations at the 110 th Scientific Assembly and Annual ...

Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this medical device maker have ...

We came across a bearish thesis on Hologic, Inc. on Value investing subreddit by Inevitable_Kick9706. In this article, we will summarize the bears’ thesis on HOLX. Hologic, Inc.’s share was trading at $74.

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused ...

Dolby (DLB) stock has sold off with software—read why its licensing model, high margins, and added patents boost value, plus key AI risks.